{
  "id": 1769614688606,
  "seqId": 119,
  "title": "RETINOBLASTOMA: THE COMPLETE CLINICAL COMPENDIUM",
  "summary": "The commonest primary malignant intraocular tumour of childhood, arising from primitive retinoblasts due to Rb gene mutations. This guide covers the critical genetics, clinical features, multidisciplinary treatments, and prognosis of this life-threatening but highly curable disease.",
  "date": "2026-01-28T15:38:08.606Z",
  "data": {
    "title": "RETINOBLASTOMA: THE COMPLETE CLINICAL COMPENDIUM",
    "summary": "The commonest primary malignant intraocular tumour of childhood, arising from primitive retinoblasts due to Rb gene mutations. This guide covers the critical genetics, clinical features, multidisciplinary treatments, and prognosis of this life-threatening but highly curable disease.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' stroke='#1d4ed8' stroke-width='2' fill='none'/><circle cx='50' cy='50' r='15' fill='#1d4ed8' opacity='0.3'/><path d='M30 50 Q 50 20 70 50 Q 50 80 30 50' stroke='#1d4ed8' fill='white'/><circle cx='55' cy='45' r='5' fill='#ef4444'/><text x='50' y='95' font-size='8' text-anchor='middle' fill='#1d4ed8' font-family='sans-serif'>Intraocular Tumour</text></svg>",
    "sections": [
      {
        "title": "Core Overview & Epidemiology",
        "icon": "analytics",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Definition: The commonest 1° malignant intraocular tumour of childhood.",
          "Origin: Arises from primitive retinoblasts of the developing retina.",
          "Genetic Basis: Loss of function of the Rb tumour suppressor gene (Chr 13q14).",
          "Lifetime Incidence: 1 in 15–20,000 births.",
          "Demographics: No gender or racial predilection.",
          "Median Age (Heritable): Under 12 months.",
          "Median Age (Sporadic): Closer to 24 months.",
          "Rare Presentation: Presentation after the age of 6 years is extremely rare."
        ]
      },
      {
        "title": "The Genetics of Retinoblastoma",
        "icon": "dna",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "center": "Knudson’s ‘Two-Hit’ Hypothesis",
          "branches": [
            "M1 & M2 Mutations: Required to initiate tumour (loss/inactivation of both Rb gene copies)",
            "M3–Mn Mutations: Subsequent mutations that determine tumour progression",
            "Genetic (Germline) Form: Every cell in the body is missing one copy (mutation at zygote stage); every photoreceptor can give rise to a tumour",
            "Somatic (Non-heritable) Form: Single retinal cell loses one copy during development (rest of body cells normal); 2nd hit is a random event"
          ]
        }
      },
      {
        "title": "Inheritance vs. Sporadic Patterns",
        "icon": "family_history",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Classification",
            "Statistical Data & Genetic Implications"
          ],
          "rows": [
            [
              "Sporadic Cases",
              "Over 90% of cases (no Family History). Most are somatic/isolated unilateral disease."
            ],
            [
              "New Germline Mutations",
              "A third of sporadic cases arise from new germline mutations (heritable to offspring but not inherited from parents)."
            ],
            [
              "Bilateral Cases",
              "40% of all cases (necessarily germline)."
            ],
            [
              "Unilateral Cases",
              "60% of all cases (could be somatic or germline). 15% of unilateral cases are germline."
            ],
            [
              "Penetrance",
              "Germline mutations are highly penetrant; over 90% of children with the Rb gene defect will develop the tumour."
            ],
            [
              "Clinical presentation",
              "Genetic cases: Multiple tumours in one or both eyes (unilateral multifocal or bilateral). Somatic cases: Always unilateral and unifocal."
            ]
          ]
        }
      },
      {
        "title": "Histology & Clinical Presentation",
        "icon": "microscope",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "H.F.F. Rosettes",
          "explanation": "Characteristic histological features: Homer Wright rosettes, Flexner–Wintersteiner rosettes, and fleurettes."
        }
      },
      {
        "title": "Clinical Signs & Symptoms",
        "icon": "visibility",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Leucocoria",
              "value": 60
            },
            {
              "label": "Strabismus",
              "value": 20
            },
            {
              "label": "dVa/Red Eye/Inflammation",
              "value": 20
            }
          ]
        }
      },
      {
        "title": "Tumour Growth & Morphology",
        "icon": "growth_curve",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Appearance: White, round retinal mass.",
          "Endophytic Growth: Growth towards vitreous with vitreous seeds.",
          "Exophytic Growth: Growth towards RPE/choroid with subretinal seeds.",
          "Mixed or Diffuse Infiltrating: Generalized retinal thickening.",
          "Calcification: Visible on ophthalmoscopy or detectable on ultrasonography."
        ]
      },
      {
        "title": "Complications (In Order of Frequency)",
        "icon": "warning",
        "type": "process",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "1. Optic nerve (± CNS) invasion.",
          "2. Anterior segment involvement: glaucoma ± buphthalmos/corneal oedema, iris invasion (heterochromia), phthisis bulbi ± pseudohypopyon, rubeosis ± hyphaema.",
          "3. Extraocular spread: e.g. orbital inflammation.",
          "4. Systemic metastasis: to bone marrow, liver, and lungs."
        ]
      },
      {
        "title": "Diagnostic Investigations",
        "icon": "biotech",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Modality",
            "Findings & Critical Notes"
          ],
          "rows": [
            [
              "Ultrasonography (US)",
              "Intralesional calcification with high internal reflectivity and acoustic shadow (detected best with low gain setting)."
            ],
            [
              "CT Scan",
              "BEST AVOIDED. Radiation magnifies risk of 2° malignancies in germline cases."
            ],
            [
              "MRI",
              "Useful for extraocular/intracranial spread, signs of IICP (Pineal blastoma/Trilateral RB), or if diagnosis is in doubt."
            ],
            [
              "Mutation Testing",
              "Essential investigation (blood/tumour tissue). Distinguishes germline vs. somatic; determines risk for fellow eye, relatives, and future offspring."
            ]
          ]
        }
      },
      {
        "title": "Staging & Treatment Principles",
        "icon": "format_list_numbered",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "International Classification: Five groups (A–E) of increasing severity for intraocular disease.",
          "Extraocular Staging: A separate staging system exists for disease outside the eye.",
          "High Cure Rate: >95% survival with appropriate treatment due to confinement within the scleral envelope.",
          "Multidisciplinary Input: Requires coordination by a specialized centre.",
          "Monitoring: Examination under anaesthesia (EUA) at decreasing frequency as the child ages; awake exams for older children.",
          "Active Phase: 4–6 cycles of chemotherapy at 3-weekly intervals with EUAs before each cycle to monitor and apply local treatment."
        ]
      },
      {
        "title": "CRITICAL CONTRAINDICATION",
        "icon": "dangerous",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "The diagnosis is CLINICAL.",
          "AVOID ANY INTRAOCULAR PROCEDURE (e.g., diagnostic biopsy).",
          "Biopsy may lead to extraocular spread, which could result in death."
        ]
      },
      {
        "title": "Interventional Treatment: Local & Radiotherapy",
        "icon": "medical_services",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Treatment",
            "Indications & Limitations"
          ],
          "rows": [
            [
              "Laser Treatment",
              "Green (532nm) or Infrared (810nm) TTT. Suitable for small tumours or post-chemoreduction. NOT effective for vitreous seeds."
            ],
            [
              "Cryotherapy",
              "Suitable for larger peripheral tumours or localized vitreous disease close to the retina."
            ],
            [
              "External Beam Radiotherapy",
              "Now reserved for diffuse disease in only eye or recurrent disease. Proton beam preferred over photons. Disadvantages: 2° malignancies (germline), cataracts, dry eyes, bony atrophy."
            ],
            [
              "Plaque Brachytherapy",
              "Sutured to sclera for hours to 4 days. Localized high dose, NO risk of 2° tumours. Effective for localized vitreous disease/elevated tumours."
            ]
          ]
        }
      },
      {
        "title": "Interventional Treatment: Chemotherapy & Surgery",
        "icon": "medication",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Chemoreduction: Shrinking tumours to a size where laser is effective. Also for vitreous/subretinal disease and metastases.",
          "Common Regimens: Carboplatin, Etoposide, and Vincristine. (Side effects: hearing loss, nephrotoxicity).",
          "Intra-arterial Chemotherapy: Delivering drugs (Melphalan, Carboplatin, Topotecan) into ophthalmic artery via transfemoral catheterization. Expensive/specialized.",
          "Intravitreal Chemotherapy: Pars plana injection of melphalan ± topotecan for resistant vitreous disease. Improved success rates.",
          "Enucleation: Oldest/most effective curative treatment. Choice for advanced uniocular disease or the worse eye in bilateral cases.",
          "Enucleation Procedure: Eye removed with long segment of optic nerve; orbital implant (18–22mm Medpor/HA/Bioceramic) inserted; later cosmetic prosthetic shell fitted."
        ]
      },
      {
        "title": "Supportive Care & Long-term Management",
        "icon": "support",
        "type": "process",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "1. Prosthesis fitting: Usually 6 weeks after enucleation surgery.",
          "2. Psychological support: For children and families dealing with loss of eye and chronic illness.",
          "3. Eye Protection: Protective eyewear for the better/remaining eye during contact sports.",
          "4. Oncological Surveillance: Long-term monitoring, especially for germline cases, by oncologists.",
          "5. Genetic Counselling: Risks to siblings/offspring; advice on 2° malignancies (smoking risks, early warning signs).",
          "6. Cataract Surgery: If needed, delay at least 1–2 years after active treatment."
        ]
      },
      {
        "title": "Prognosis and Late Risks",
        "icon": "trending_up",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Untreated Survival: Death within 2 years due to local invasion and metastasis.",
          "Spontaneous Events: Tumour may stop growing (retinoma) or necrose (phthisis bulbi).",
          "Overall Survival: 95% in the developed world.",
          "Poor Prognostic Factors: Tumour size, optic nerve involvement, extraocular spread, and older age.",
          "Germline Risks: Increased risk of pineoblastoma (trilateral RB), ectopic intracranial RB, and osteogenic/soft tissue sarcomas (increased by radiation)."
        ]
      },
      {
        "title": "Screening Protocols",
        "icon": "person_search",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "center": "Screening for Relatives",
          "branches": [
            "Purpose: Early detection/treatment to save eyes and lives",
            "Offered if: Mutation is positive in index case OR mutation unknown and risk cannot be excluded",
            "Not Needed if: Relative tests negative for the specific mutation",
            "Resource Management: Approach helps avoid unnecessary screening and saves resources"
          ]
        }
      },
      {
        "title": "Final Clinical Summary",
        "icon": "description",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Understanding the genetics of retinoblastoma is critical in planning management. The information gained from mutation testing often helps distinguish between germline and somatic cases, which has major implications for determining the risk to the fellow eye, unaffected relatives, and future siblings and offspring. Treatment requires significant multidisciplinary input and coordinated care in specialized centres."
      }
    ],
    "chapterId": "tumours"
  },
  "chapterId": "neuro",
  "_newlyImported": 1769614688606,
  "communityId": "sub_1769581773585_4fhnk8m0m",
  "communityAuthor": "Dodi",
  "communityDate": "2026-01-28T06:29:33.586Z",
  "_serverSynced": true
}